Diabetes drug reduces risk of heart attacks, strokes from air pollution – Study

scanty walk ways at the National hospital Abuja as a result of the ongoing strike.
National hospital Abuja

A common, safe and inexpensive drug for Type 2 diabetes, metformin, decreases the risk of heart attacks and strokes caused by air pollution and reducing inflammation in the lungs that triggers clotting, according to a U.S study.

In the study published in Cell Press, a paediatric formulation of metformin was given to mice in their drinking water for three days.

It was an equivalent concentration to the dose people take for diabetes and the mice were exposed to air pollution in a specially designed chamber that concentrates the particles.

When the mice were exposed to air pollution in the laboratory, their macrophages released an inflammatory molecule called IL-6, linked to heart attacks and strokes.

Metformin prevented the release of IL-6 and reduced the speed at which clots formed after an injury. The same findings were seen in lung macrophages from humans.

Three years ago, Northwestern University (NU) professor of Medicine and Cell Biology and his colleagues, Mr Chandel, found that metformin inhibits cancer progression.

They also discovered that metformin slows mitochondrial metabolism to prevent the growth of cancer.

To prove that targeting the mitochondria in macrophages could prevent inflammation in response to pollution, NU Professor of Airway Diseases, Scott Budinger and Chandel created mice where lung macrophages lacked key mitochondrial proteins.

Like the mice treated with metformin, these mice were protected against pollution-induced inflammation.

These results suggest that “metformin is a pharmacological way of doing the same thing,” Mr Chandel explained.

“We know it’s an anti-diabetic drug, it can be an anti-cancer drug, and now our study suggests it’s a reasonable anti-inflammatory drug.

“These findings suggest metformin as a potential therapy to prevent some of the premature deaths attributable to air pollution exposure worldwide.”

Currently, Chandel and Budinger are determining whether metformin can target mitochondrial metabolism to prevent or slow aging and age-related diseases including diabetes, inflammation, cancer and neurodegeneration.

Meanwhile, more than 100 million people take metformin worldwide.


Support PREMIUM TIMES' journalism of integrity and credibility


Good journalism costs a lot of money. Yet only good journalism can ensure the possibility of a good society, an accountable democracy, and a transparent government.

For continued free access to the best investigative journalism in the country we ask you to consider making a modest support to this noble endeavour.

By contributing to PREMIUM TIMES, you are helping to sustain a journalism of relevance and ensuring it remains free and available to all.


NEVER MISS A THING AGAIN! Subscribe to our newsletter

* indicates required


Now available on

  Premium Times Android mobile applicationPremium Times iOS mobile applicationPremium Times blackberry mobile applicationPremium Times windows mobile application

TEXT AD: This space is available for a Text_Ad.. Call Willie on +2347088095401 for more information

All rights reserved. This material and any other material on this platform may not be reproduced, published, broadcast, written or distributed in full or in part, without written permission from PREMIUM TIMES.